secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001171843-23-002887
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies
-------------------------------------------------------------------------------

- Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).
- Cash, equivalents & securities $278.4M at March 31, 2023; sufficient through 2025.
- Phase 2 CSU enrollment completion expected Q3 2023; topline data late 2023/Q1 2024.
- Phase 2 EoE study initiation expected June 2023; CDX-585 enters clinic mid-2023.
- R&D expenses $26.8M (up from $17.1M) driven by barzolvolimab trials and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/0001171843-23-002887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/f8k_050423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer